background
studi
evalu
rel
crossprotect
confer
infect
differ
group
virus
studi
sequenti
infect
human
investig
presenc
shortliv
rel
crossprotect
confer
specif
prior
viral
infect
subsequ
febril
respiratori
ill
fri
method
men
enlist
basic
militari
train
decemb
decemb
recruit
first
fri
studi
entri
point
resplex
ii
assay
realtim
polymeras
chain
reaction
assay
use
detect
viral
pathogen
nasal
wash
sampl
surviv
analys
perform
determin
whether
infect
particular
virus
confer
shortliv
rel
crossprotect
fri
result
prior
infect
adenoviru
hazard
ratio
hr
confid
interv
ci
influenza
viru
hr
ci
confer
rel
protect
subsequ
fri
episod
result
statist
signific
even
adjust
interv
enlist
fri
p
adenovirusposit
particip
fri
episod
tend
protect
subsequ
infect
adenoviru
coronaviru
enterovirusrhinoviru
influenza
viru
p
men
influenza
virusposit
fri
episod
tend
protect
subsequ
infect
adenoviru
p
influenza
viru
p
conclus
prior
adenoviru
influenza
viru
infect
confer
crossprotect
subsequ
fri
episod
rel
prior
infect
due
circul
virus
viral
interfer
describ
phenomenon
wherebi
prior
viral
infect
potenti
exert
effect
subsequ
infect
virus
edward
jenner
first
report
herpet
infect
observ
crossprotect
subsequ
develop
vaccinia
lesion
isaac
lindenmann
discov
role
interferon
viral
interfer
sinc
crossprotect
observ
anim
virus
possibl
mechan
elabor
multipl
anim
model
human
popul
timeseri
analys
demonstr
epidem
involv
particular
viru
influenc
tempor
epidem
involv
famili
respiratori
virus
sever
casecontrol
crosssect
studi
also
show
codetect
respiratori
virus
less
frequent
observ
infect
caus
differ
respiratori
virus
occur
independ
howev
evid
studi
sequenti
infect
human
would
provid
morerobust
evid
viral
infect
reduc
risk
subsequ
infect
differ
group
virus
clarifi
whether
crossprotect
effect
differ
differ
type
virus
previous
report
rollout
routin
trival
season
influenza
vaccin
singapor
arm
forc
accompani
dramat
declin
incid
laboratoryconfirm
influenza
viru
infect
much
less
notic
decreas
overal
incid
febril
respiratori
ill
fri
episod
subsequ
increas
incid
adenoviru
infect
appear
least
timeseri
data
account
degre
replac
influenza
viru
infect
avert
vaccin
articl
set
clarifi
relationship
specif
prior
viral
infect
subsequ
fri
episod
young
singaporean
men
undergo
basic
militari
train
bmt
reanalyz
singapor
arm
forc
fri
surveil
program
data
use
surviv
analys
assess
whether
evid
individu
level
infect
particular
virus
confer
shortliv
rel
crossprotect
subsequ
fri
episod
includ
caus
viru
group
sinc
may
singapor
arm
forc
oper
sentinel
fri
surveil
program
major
recruittrain
center
recruit
develop
fri
would
report
primari
healthcar
clinic
assess
would
receiv
treatment
would
typic
given
home
leav
day
regular
consult
hour
recruit
meet
inclus
criteria
ie
temperatur
plu
either
cough
sore
throat
ask
particip
studi
follow
receipt
written
inform
consent
patient
administ
questionnair
collect
nasal
wash
sampl
side
nose
exclud
repeat
consult
patient
determin
recov
earlier
ill
episod
studi
cover
recruit
undergo
bmt
decemb
decemb
inactiv
influenza
vaccin
routin
administ
recruit
contraind
initi
monoval
influenza
vaccin
miv
contain
pandem
influenza
viru
recruit
enlist
decemb
octob
miv
supersed
trival
influenza
vaccin
tiv
includ
recruit
enlist
novemb
decemb
studi
review
approv
singapor
militari
joint
medic
committe
research
nation
univers
singapor
ethic
review
committe
nation
univers
singapor
institut
review
board
refer
sampl
sent
viral
transport
medium
copan
diagnost
murrieta
ca
etiolog
test
within
hour
collect
studi
period
resplex
ii
multiplex
polymeras
chain
reaction
assay
use
decemb
june
detect
viral
pathogen
replac
inhous
viral
multiplex
polymeras
chain
reaction
assay
supplementari
materi
bmt
tailor
physic
medic
vocat
need
recruit
major
enlist
main
intak
type
standard
durat
around
week
small
proport
mix
shorter
cours
term
other
dropout
rate
low
studi
clinic
serv
healthcar
need
recruit
train
center
henc
abl
reanalyz
individu
fri
episod
cohort
studi
link
consult
episod
code
subject
identifi
first
fri
episod
given
particip
serv
point
entri
studi
individu
particip
accumul
followup
time
figur
subsequ
fri
episod
event
interest
episod
accumul
followup
time
exit
date
bmt
particip
episod
contribut
addit
followup
interv
subsequ
episod
subsequ
consult
fri
episod
addit
definit
event
interest
episod
posit
respiratori
virus
test
specif
group
etiolog
agent
group
agent
use
broad
categori
accommod
chang
test
protocol
studi
period
reflect
viru
taxonomi
adenovirus
adv
speci
b
e
other
type
undetermin
coronavirus
cov
cov
enterovirus
rhinovirus
erv
human
metapneumoviru
hmpv
influenza
viru
fluv
influenza
viru
pandem
influenza
viru
influenza
viru
influenza
virusposit
sampl
subtyp
undetermin
influenza
b
viru
human
parainfluenza
viru
hpiv
type
respiratori
syncyti
viru
rsv
rsva
rsvb
viru
categori
describ
also
exposur
interest
investig
whether
fri
episod
caus
one
viru
group
confer
rel
greater
protect
subsequ
fri
episod
fri
episod
test
neg
viru
group
individu
subsequ
fri
episod
exposur
prior
infect
regard
cumul
instanc
scenario
figur
subsequ
fri
episod
hmpv
exposur
occur
interv
c
cov
exposur
occur
interv
b
c
adv
occur
interv
potenti
confound
includ
year
surveil
program
particip
age
ethnic
type
bmt
intak
histori
smoke
asthma
includ
childhood
asthma
receipt
influenza
vaccin
fri
episod
assess
whether
particip
receiv
miv
tiv
base
selfreport
vaccin
histori
year
prior
first
fri
episod
sinc
antibodi
titer
vaccin
effect
could
wane
thereaft
supplement
singapor
arm
forc
record
vaccin
receiv
enlist
sinc
fri
episod
concentr
differenti
bmt
cours
adjust
effect
use
fri
incid
rate
success
phase
time
enlist
intak
type
figur
supplementari
materi
observ
time
split
subinterv
observ
period
straddl
differ
bmt
phase
analyz
multilevel
model
framework
figur
framework
includ
random
effect
term
bmt
compani
particip
belong
within
nest
interv
delin
consecut
fri
episod
within
turn
nest
subinterv
straddl
bmt
phase
level
model
model
level
model
omit
subinterv
use
adjust
fri
incid
model
stratifi
subinterv
whether
end
week
week
initi
fri
episod
use
first
fri
episod
particip
episod
bmt
phase
wk
figur
scenario
febril
respiratori
ill
fri
defin
consult
primari
healthcar
clinic
temperatur
detect
plu
either
cough
sore
throat
episod
interv
timetoev
analys
scenario
subsequ
fri
episod
particip
accumul
followup
time
first
fri
episod
date
exit
basic
militari
train
bmt
scenario
followup
time
accru
first
second
episod
interv
level
therefor
redund
model
adjust
fri
incid
rate
time
enlist
henc
exclud
bmt
intak
type
term
data
use
estim
incid
rate
unavail
present
simpl
tabul
visual
data
particip
episod
level
use
fisher
exact
test
appropri
investig
fri
caus
specif
viru
famili
affect
subsequ
risk
fri
episod
rel
unexpos
kaplanmei
plot
logrank
test
well
multilevel
surviv
analys
surviv
time
model
use
weibul
distribut
adjust
potenti
confound
also
investig
whether
exposur
fluv
adv
affect
subsequ
risk
fri
episod
risk
fri
specif
pathogen
use
kaplanmei
plot
logrank
test
howev
multivari
analysi
perform
sampl
size
limit
restrict
event
interest
specif
pathogen
analys
use
stata
stata
colleg
station
tx
p
valu
consid
statist
signific
studi
includ
fri
episod
among
particip
enrol
approxim
year
total
fri
episod
posit
viru
includ
panel
tabl
fri
episod
identifi
viru
less
like
without
identifi
viru
follow
subsequ
fri
episod
vs
respect
p
subsequ
fri
episod
virus
group
rare
across
viru
group
figur
former
pattern
observ
latter
routin
tiv
administr
data
shown
among
fri
episod
identifi
viru
proport
follow
fri
episod
decreas
gradual
among
fri
episod
without
identifi
viru
figur
rel
protect
subsequ
fri
episod
also
observ
advposit
versu
advneg
episod
figur
likewis
fluv
infect
figur
result
statist
signific
p
howev
signific
relationship
observ
cov
erv
hmpv
hpiv
rsv
supplementari
figur
model
account
hierarch
data
structur
covari
gave
similar
result
tabl
rel
episod
without
identifi
viru
adv
hazard
ratio
hr
ci
fluv
hr
ci
infect
confer
signific
protect
subsequ
fri
episod
adv
fluv
infect
remain
significantli
protect
adjust
fri
incid
time
enlist
model
addit
variabl
stratifi
subinterv
whether
end
week
week
initi
fri
episod
model
interestingli
hazard
subsequ
fri
episod
significantli
lower
subinterv
end
week
initi
episod
vs
end
week
initi
episod
hr
ci
moreov
evid
interact
fluv
p
interact
stratifi
hr
fluv
infect
subinterv
end
week
week
initi
fri
episod
ci
p
ci
p
respect
supplementari
tabl
corrobor
find
altern
approach
use
crude
fri
incid
rate
base
underli
bmt
popul
risk
follow
adv
fluv
infect
incid
rate
subsequ
fri
episod
consist
lower
averag
recruit
bmt
intak
type
moreov
compar
full
cours
durat
analys
censor
week
enlist
show
stronger
protect
effect
prior
fluv
infect
likewis
incid
rate
ratio
stratifi
bmt
intak
type
reveal
increas
protect
prior
fluv
infect
shorter
cours
durat
tabl
advposit
episod
tend
protect
subsequ
infect
adv
p
also
viru
group
model
adjust
studi
year
type
bmt
intak
age
ethnic
smoke
histori
histori
asthma
influenza
vaccin
c
adjust
fri
incid
rate
time
enlist
time
interv
rel
prior
consult
episod
episod
includ
exposur
event
interest
bmt
type
includ
adjust
fri
incid
rate
time
enlist
express
fri
episod
per
enliste
day
defin
illustr
method
figur
time
interv
rel
prior
consult
episod
episod
includ
exposur
event
interest
bmt
type
includ
e
adjust
fri
incid
rate
time
sinc
enlist
express
number
fri
episod
per
enlisteeday
defin
illustr
method
figur
whether
interv
assess
week
week
prior
episod
initi
episod
exposur
interest
second
episod
event
interest
bmt
type
includ
figur
crossprotect
fluv
episod
appar
full
data
set
supplementari
figur
howev
routin
administr
tiv
ie
octob
fluvposit
episod
tend
protect
subsequ
fluv
infect
enliste
recent
receiv
tiv
p
supplementari
figur
none
viru
group
confer
signific
groupspecif
protect
supplementari
tabl
studi
provid
evid
fri
episod
due
respiratori
virus
certain
categori
reduc
risk
subsequ
fri
episod
basic
militari
train
rel
fri
episod
due
respiratori
virus
among
virus
protect
effect
strongest
follow
adv
fluv
episod
adv
infect
confer
protect
subsequ
infect
adv
crossprotect
group
commonli
circul
virus
bmt
cov
erv
fluv
fluv
infect
confer
signific
protect
subsequ
adv
infect
observ
influenza
protect
subsequ
episod
influenza
mostli
due
typessubtyp
data
period
prior
routin
tiv
administr
also
consist
report
human
anim
model
studi
previou
timeseri
analys
demonstr
viral
interfer
account
season
factor
suggest
epidem
influenza
viru
rhinoviru
infect
tend
shift
time
epidem
virus
other
use
casecontroltyp
analys
codetect
data
demonstr
rhinoviru
infect
exposur
invers
associ
probabl
observ
adenoviru
influenza
viru
infect
latter
viral
infect
frame
outcom
interest
howev
studi
militari
recruit
adenoviru
domin
fri
agent
wang
et
al
use
casecontrol
analysi
demonstr
revers
phenomenonthat
adenoviru
infect
exposur
reduc
odd
rhinoviru
infect
outcom
interest
howev
note
anoth
interpret
result
rhinoviru
infect
reduc
risk
subsequ
adenoviru
infect
oppos
frame
outcom
exposur
codetect
studi
highlight
issu
interpret
result
crosssect
casecontrol
design
sequenc
infect
ascertain
distinguish
work
use
cohort
studi
design
identifi
tempor
sequenc
initi
subsequ
fri
episod
previou
studi
could
observ
posit
specif
viru
group
essenti
compar
neg
virus
test
therefor
analys
assess
whether
exampl
infect
erv
group
confer
protect
rel
individu
recent
viral
infect
supplementari
tabl
suggest
rel
enlist
recruit
main
bmt
intak
type
incid
rate
subsequ
fri
episod
higher
full
cours
durat
bmt
intak
type
respect
appli
viru
group
except
adv
fluv
group
possibl
due
confound
common
risk
factor
repeat
fri
individu
level
howev
shortest
bmt
type
censor
data
shorter
period
enlist
incid
rate
reduc
viru
group
rel
averag
rate
recruit
follow
enlist
fri
episod
whole
incid
rate
ratio
ci
p
data
censor
week
enlist
supplementari
tabl
observ
therefor
suggest
viral
caus
fri
adv
fluv
may
also
confer
short
timelimit
protect
also
corrobor
find
tabl
reduc
hazard
subsequ
fri
episod
occur
first
week
follow
initi
fri
episod
rel
latter
period
fluv
strongli
protect
former
period
differ
virus
may
thu
one
degre
virus
confer
weak
timelimit
protect
stronger
effect
adenoviru
influenza
viru
becom
appar
aggreg
data
full
cours
durat
one
mechan
consist
shortliv
crossprotect
trigger
interferonstimul
gene
cytokin
caus
nearbi
cell
respiratori
tract
enter
antivir
state
altern
transient
crossprotect
could
result
infectioninduc
behavior
chang
improv
hand
hygien
follow
fri
short
durat
reduc
exposur
new
pathogen
furlough
home
leav
howev
like
inadequ
explain
extent
crossprotect
observ
adenoviru
influenza
viru
infect
rel
fri
episod
propos
mechan
competit
receptorbind
site
intracellular
host
machineri
replic
unfavor
physiolog
state
host
high
bodi
temperatur
upon
initi
infect
applic
protect
coinfect
demonstr
sequenti
infect
find
sever
implic
provid
explan
previous
suspect
basi
timeseri
analys
influenza
epidem
potenti
delay
rsv
epidem
also
add
bodi
evid
motiv
search
caus
mechan
crossprotect
among
viral
infect
provid
addit
clue
given
rel
rank
viru
famili
confer
crossprotect
suggest
focus
search
mechan
common
factor
induc
adenoviru
influenza
viru
notabl
previou
studi
suggest
infect
infect
may
sever
like
present
febril
ill
higher
temperatur
infect
due
common
circul
viru
famili
support
cytokinemedi
antivir
effect
find
mean
induc
crossprotect
without
sever
side
effect
could
potenti
lead
intervent
may
particularli
use
context
exposur
danger
virus
specif
vaccin
antivir
agent
howev
studi
limit
studi
popul
larg
compris
healthi
young
adult
key
circul
virus
group
differ
somewhat
observ
gener
popul
singapor
also
exclud
respiratori
ill
episod
meet
inclus
criteria
temperatur
also
acknowledg
captur
data
fri
episod
like
incomplet
consult
outsid
offic
hour
weekend
traine
home
leav
miss
surveil
program
howev
argu
restrict
studi
febril
case
incomplet
captur
data
bias
toward
null
thu
negat
main
find
rel
crossprotect
subsequ
fri
episod
confer
adenoviru
influenza
viru
infect
summari
studi
demonstr
broadbas
viral
interfer
popul
militari
recruit
infect
adenoviru
influenza
viru
famili
confer
signific
crossprotect
effect
subsequ
fri
episod
rel
circul
virus
durat
crossprotect
effect
extend
beyond
previous
demonstr
studi
viral
coinfect
studi
point
way
research
underli
mechan
broadbas
antivir
activ
human
host
deserv
greater
studi
supplementari
materi
avail
journal
infecti
diseas
onlin
consist
data
provid
author
benefit
reader
post
materi
copyedit
sole
respons
author
question
comment
address
correspond
author
